AMRX Stock | | | USD 8.38 0.01 0.12% |
Director
Mr. Ted Nark is Independent Director of the Company. Mr. Nark has served as Managing Director of KRG Capital Partners, a Denverbased 2 billion private equity fund, since 2007. In that role, Mr. Nark has led the identification, negotiation and due diligence of new acquisitions and has worked with portfolio companies and maintained relationships with limited partners. While at KRG, Mr. Nark has led the acquisition and successful monetization of companies including Convergint Technologies, Diversified Food Services and Petrochoice. From 2006 to 2007, Mr. Nark was a Partner at Leonard Green Partners and from 2002 to 2006, he served as Chief Executive Officer and Chairman of the Board of White Cap Construction Supply, a Leonard Greenowned distributor of construction hardware, tools and materials to professional contractors in the United States. Previously, Mr. Nark served as Chief Executive Officer of Corporationrationrate Express Australia and Group President at Corporationrationrate Express Inc. Mr. Nark is currently a board member of several private companies such as Convergint Technologies, Western Windows, Trafficware, and The Maroon Group. Mr. Nark has previously served on the Boards of Corporationrationrate Express Australia, Fort Dearborn, White Cap Construction Supply, FTD, Leslies Pools, Gaiam, Real Goods Solar and Claim Jumper since 2018.
Age | 62 |
Tenure | 6 years |
Address | 400 Crossing Boulevard, Bridgewater, NJ, United States, 08807 |
Phone | 908 947 3120 |
Web | https://amneal.com |
Nark received a BS from Washington State University.
Amneal Pharmaceuticals, Management Efficiency
The company has return on total asset
(ROA) of
0.0594 % which means that it generated a profit of $0.0594 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(1.8577) %, meaning that it created substantial loss on money invested by shareholders. Amneal Pharmaceuticals,'s management efficiency ratios could be used to measure how well Amneal Pharmaceuticals, manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Capital Employed is likely to rise to 0.12 in 2024, despite the fact that
Return On Tangible Assets are likely to grow to
(0.04). At this time, Amneal Pharmaceuticals,'s
Non Currrent Assets Other are fairly stable compared to the past year.
Intangible Assets is likely to rise to about 933.3
M in 2024, whereas
Total Assets are likely to drop slightly above 3.2
B in 2024.
Amneal Pharmaceuticals, Class currently holds 2.75
B in liabilities. Amneal Pharmaceuticals, has a current ratio of 1.71, which is within standard range for the sector. Note, when we think about Amneal Pharmaceuticals,'s use of debt, we should always consider it together with its cash and equity.
Similar Executives
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. Amneal Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 7000 people. Amneal Pharmaceuticals, Class (AMRX) is traded on New York Stock Exchange in USA and employs 7,850 people. Amneal Pharmaceuticals, is listed under Pharmaceuticals category by Fama And French industry classification.
Management Performance
Amneal Pharmaceuticals, Leadership Team
Elected by the shareholders, the Amneal Pharmaceuticals,'s board of directors comprises two types of representatives: Amneal Pharmaceuticals, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amneal. The board's role is to monitor Amneal Pharmaceuticals,'s management team and ensure that shareholders' interests are well served. Amneal Pharmaceuticals,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amneal Pharmaceuticals,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sanjay Jain, President Operations | |
| Anastasios Konidaris, Chief Financial Officer, Executive Vice President | |
| John Kiely, Independent Director | |
| Gautam Patel, Director | |
| Pranav Mehta, Senior Management | |
| Nikita Shah, Chief Human Resource Officer, Executive Vice President, Strategic Planning Officer | |
| Paul Meister, Independent Chairman of the Board | |
| Jason Esq, Chief VP | |
| Andrew Boyer, Executive Vice President, Chief Commercial Officer - Generics | |
| Ted Nark, Independent Director | |
| Jeffrey George, Independent Director | |
| Shlomo Yanai, Independent Director | |
| Nikunj Patel, Head Ltd | |
| Gregory Sgammato, Senior Development | |
| Chintu Patel, Co-Chief Executive Officer, Co-Founder, Director | |
| Stephen Manzano, Senior Vice President, General Counsel and Corporate Secretary | |
| Sanjiv Patel, VP Operations | |
| Emily Alva, Independent Director | |
| Anthony DiMeo, Director Relations | |
| Joseph Greer, Senior Vice President - Global Quality Management | |
| Jason Daly, Senior Vice President Chief Legal Officer and Corporate Secretary | |
| Apurva Saraf, Senior Vice President - Corporate Development | |
| Chintu RPh, CoCEO CoFounder | |
| RPh RPh, CoCEO CoFounder | |
| J Buchi, Independent Director | |
| Chirag Patel, President, Co-Chief Executive Officer, Co-Founder, Director | |
| Joseph Todisco, Executive Vice President, Chief Commercial Officer - Specialty | |
Amneal Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amneal Pharmaceuticals, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Amneal Stock Analysis
When running Amneal Pharmaceuticals,'s price analysis, check to
measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to
predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.